Advanced hormone receptor-positive/human epidermal growth factor receptor 2-positive invasive ductal carcinoma with cecal metastasis: A case report

被引:0
|
作者
Yang, Si-Yuan [1 ,2 ]
Zhang, Ji [1 ]
Yang, Zhuang-Qing [1 ,2 ]
Duan, Jia-Jun [1 ]
Zhang, Ying [3 ]
Li, Ming-Ke [4 ]
Wang, Lei [1 ]
Ye, Chun-mei [1 ]
Nie, Jian-Yun [1 ,5 ]
机构
[1] Kunming Med Univ, Yunnan Canc Hosp, Yunnan Canc Ctr, Dept Breast Surg 3,Affiliated Hosp 3, Kunming, Peoples R China
[2] Kunming Med Univ, Kunming, Peoples R China
[3] Third Peoples Hosp Yunnan Prov, Dept Thyroid & Breast Surg, Kunming, Peoples R China
[4] Kunming Med Univ, Dept Digest Med, Affiliated Hosp 1, Kunming, Peoples R China
[5] Kunming Med Univ, Yunnan Canc Hosp, Affiliated Hosp 3, Dept Breast Surg 3, 519 Kunzhou Rd, Kunming 650118, Yunnan, Peoples R China
关键词
Breast Cancer; Gastrointestinal metastases; Cecal Metastasis; Invasive Ductal Carcinoma; Case Report; BREAST-CANCER;
D O I
10.1177/00368504231201043
中图分类号
G40 [教育学];
学科分类号
040101 ; 120403 ;
摘要
The incidence of gastrointestinal metastases from breast cancer (BC) is low. We report a special case of Luminal B (Hormone Receptor positive [HR+]/Human Epidermal Growth Factor receptor 2-positive [HER-2+]) BC. The patient presented with asymptomatic brain metastases two years after radical surgery for modified breast cancer and developed right lower abdominal pain during relief therapy. Electronic gastroenteroscopy revealed inflammatory changes in the cecal mucosa. These changes were confirmed on pathology to be cecal metastasis from BC. The patient's condition was stabilised after treatment with an antibody-drug conjugate (ADC). For patients with BC who develop appendicitis-like symptoms after treatment for invasive ductal carcinoma of the breast, clinicians should be fully aware that the possibility of cecal metastasis needs to be considered, despite the very low probability of occurrence.
引用
收藏
页数:9
相关论文
共 50 条
  • [21] Clinicopathological features of and neoadjuvant therapy for human epidermal growth factor receptor 2-positive classic invasive lobular carcinoma
    Huang, Xiao
    Chen, Hui
    Ding, QingQing
    Robinson, Melissa K.
    Moseley, Tanya W.
    Bassett, Roland L.
    Tang, Guilin
    Lim, Bora
    Sahin, Aysegul A.
    HUMAN PATHOLOGY, 2021, 117 : 51 - 59
  • [22] Response of human epidermal growth factor receptor 2-positive colorectal cancer to lapatinib monotherapy:A case report
    Ji-Lin Guan
    Jian-Hua Liu
    Qing Wang
    Yu-Wei Cong
    Yao-Xu Chen
    Ke-Fei Huang
    Meng-Li Huang
    Ling Huang
    World Journal of Gastrointestinal Oncology, 2020, (09) : 1065 - 1072
  • [23] Response of human epidermal growth factor receptor 2-positive colorectal cancer to lapatinib monotherapy: A case report
    Guan, Ji-Lin
    Liu, Jian-Hua
    Wang, Qing
    Cong, Yu-Wei
    Chen, Yao-Xu
    Huang, Ke-Fei
    Huang, Meng-Li
    Huang, Ling
    WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2020, 12 (09) : 1065 - 1072
  • [24] Pyrotinib in the treatment of human epidermal growth factor receptor 2-positive metastatic breast cancer A case report
    Dai, Jiali
    Chen, Yuetong
    Tang, Cuiju
    Wei, Xiaowei
    Gong, Yang
    Wei, Jingsun
    Gu, Dongying
    Chen, Jinfei
    MEDICINE, 2020, 99 (25) : E20809
  • [25] Fulvestrant in the treatment of hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: A review
    Li, Junjie
    Wang, Zhonghua
    Shao, Zhimin
    CANCER MEDICINE, 2019, 8 (05): : 1943 - 1957
  • [26] First-line treatments and clinical outcomes for hormone receptor-positive, human epidermal growth factor 2-positive advanced or metastatic breast cancer: A systematic literature review
    Chang, R.
    Law, E.
    Xie, J.
    Cha, A. S.
    Chen, X.
    Fang, H.
    Kurosky, S. K.
    ANNALS OF ONCOLOGY, 2021, 32 : S470 - S470
  • [27] Efficacy of Sacituzumab Govitecan in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer
    Qureshi, Zaheer
    Jamil, Abdur
    Fatima, Eeshal
    Altaf, Faryal
    Siddique, Rimsha
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2024, 47 (11): : 526 - 534
  • [28] Delaying Chemotherapy in the Treatment of Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer
    Brufsky, Adam M.
    CLINICAL MEDICINE INSIGHTS-ONCOLOGY, 2015, 9 : 137 - 147
  • [29] Excellent Response to Fam-Trastuzumab Deruxtecan for Human Epidermal Growth Factor Receptor 2-Positive Salivary Duct Carcinoma With CNS Metastasis: A Case Report
    Angeli Gazola, Antonia
    Wong, Deborah
    Chin, Robert
    Nikitas, John
    Kim, Christine J.
    Hart, Steven D.
    St John, Maie
    Chai-Ho, Wanxing
    JCO PRECISION ONCOLOGY, 2022, 6
  • [30] Therapeutic Strategies for the Management of Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Positive (HR+/HER2+) Breast Cancer: A Review of the Current Literature
    Thanopoulou, Eirini
    Khader, Leila
    Caira, Morena
    Wardley, Andrew
    Ettl, Johannes
    Miglietta, Federica
    Neven, Patrick
    Guarneri, Valentina
    CANCERS, 2020, 12 (11) : 1 - 29